Convalescent plasma therapy prevents acute respiratory distress syndrome in patients with sars-cov-2 virus disease

摘要: BACKGROUND: SARS-CoV-2 disease 2019 is a pandemic with no specific therapeutic agents and substantial mortality. The success of convalescent plasma therapy based on the transfused had high concentrations anti-SARS-CoV-2 antibodies, safe preparation serum to eliminate potential risk factors, such as transmission viruses via transfusion. STUDY DESIGN AND METHODS : Five patients laboratory confirmed COVID-19, diagnosed using reverse transcriptase–polymerase chain reaction (RT-PCR) classified like care seriously non-ventilated moderate hypoxemia were received 300 mL treatment. Each donation was tested for antibody titersIgG class by UMELISA. units an average titer 836.00 ± 617.155. time interval between onset symptoms transfusion 9 days (7.20± 3). Before after each transfusion, clinical parameters evaluated. RESULTS: At 24-hour oxygen partial pressure increased from medium value 70.4 101.6 mm Hg, C-reactive protein lactate dehydrogenase enzyme values decreased in 3 5 patients; however, ferritin all patients. Post-transfusion hospital discharge 48 hours 12 PCR negative days. No adverse reactions reported. CONCLUSION :This report emphasis about efficacy security infected preventive severe respiratory distress virus disease.